Due to recent formulary changes, patients covered by Medicare, Medicaid and many major commercial insurance plans should have more access and coverage for their Mitigare® (Colchicine) 0.6 mg Capsules and Generic Colchicine Capsules prescriptions.
Click on our announcements below to find out more about each coverage update.
*Managed Markets Insight & Technology, LLC database and formulary status as of January 2021.
Recent Announcements
All the following are Effective January 1, 2021
Mitigare® (Colchicine) 0.6 mg Capsules are now Preferred on the Humana MEDICARE Part D formulary and Humana Commercial formulary.
Details: Colcrys® (colchicine, USP) 0.6 mg tablets, colchicine tablets, and colchicine capsules require prior authorization on the Humana MEDICARE Part D formulary.
Mitigare® (Colchicine) 0.6 mg Capsules are now Preferred on the CVS SilverScript® MEDICARE Part D formulary.
Details: Colcrys® (colchicine, USP) 0.6 mg tablets and colchicine capsules require prior authorization on the CVS SilverScript® MEDICARE Part D formulary.
Mitigare® (Colchicine) 0.6 mg Capsules are now a Preferred Agent on the Cigna MEDICARE Part D formulary.
Mitigare® (Colchicine) 0.6 mg Capsules are now Preferred on the BCBS-AZ Blue Medicare RX formulary.
Mitigare® (Colchicine) 0.6 mg Capsules are now a Preferred on Wisconsin Medicaid Formulary.
Details: Colcrys® (colchicine, USP) 0.6 mg tablets, colchicine tablets, and colchicine capsules require prior authorization on Wisconsin Medicaid Formulary.
Mitigare® (Colchicine) 0.6 mg Capsules are now a Preferred Agent on the Aetna MEDICARE Part D formulary.
Effective October 1, 2020
Mitigare® (Colchicine) 0.6 mg Capsules are now Preferred on Michigan Medicaid Preferred Drug List (PDL).
Details: Colcrys® (colchicine, USP) 0.6 mg tablets, colchicine tablets, and colchicine capsules require prior authorization on Michigan Medicaid PDL.
Effective February 1, 2020
Mitigare® (Colchicine) 0.6 mg Capsules are now Preferred on Horizon Blue Cross of New Jersey commercial formulary.
Details: Colcrys® (colchicine, USP) tablets, colchicine tablets, and colchicine capsules are non-formulary on the Horizon Blue Cross of New Jersey commercial formulary.
Effective January 1, 2020
Mitigare® (Colchicine) 0.6 mg Capsules are now Preferred on the Blue Cross Blue Cross MedicareRx Illinois Part D.
Effective January 1, 2020
Mitigare® (Colchicine) 0.6 mg Capsules are now Preferred on the Blue Cross Blue Cross MedicareRx Texas Part D.
Effective January 1, 2020
Generic Colchicine 0.6 mg Capsules are now Preferred on AARP Medicare Advantage.
Effective January 1, 2020
Mitigare® (Colchicine) 0.6 mg Capsules are now Preferred on the Blue Cross Blue Shield Oregon commercial formulary.*
Details: Colcrys® (colchicine, USP) tablets, colchicine tablets and colchicine capsules are non-formulary on the Blue Cross Blue Shield Oregon commercial formulary.
Effective January 1, 2020
Mitigare® (Colchicine) 0.6 mg Capsules are now Preferred on the Regence BlueShield Washington commercial formulary.*
Details: Colcrys® (colchicine, USP) tablets, colchicine tablets and colchicine capsules are non-formulary on Regence BlueShield Washington commercial formulary.
Effective January 1, 2020
Generic Colchicine 0.6 mg Capsules are now Preferred on the Ohio Medicaid Unified Preferred Drug List (UPDL).
Effective January 1, 2020
Mitigare® (Colchicine) 0.6 mg Capsules and Generic Colchicine Capsules are now Preferred Agents on Cigna Medicare Part D.
Details: Colcrys® (colchicine, USP) tablets are non-formulary and colchicine tablets are non-preferred on Cigna Medicare Part D.
Other Updates
Effective December 2, 2019
Mitigare® (Colchicine) 0.6 mg Capsules is now the Preferred Brand on the Rhode Island Medicaid Preferred Drug List.*
Details: Colcrys® (colchicine, USP) tablets and colchicine capsules require prior authorization on Rhode Island Medicaid Preferred Drug List.
Effective October 1, 2019
Mitigare® (Colchicine) 0.6 mg Capsules is the Only Preferred Brand on the Alabama Medicaid Preferred Drug List (PDL).*
Details: Generic Colchicine Capsules are also preferred on the Alabama PDL.* All other products in this category are either non-preferred or require prior authorization on the Alabama PDL.
Effective July 1, 2019
Mitigare® (Colchicine) 0.6 mg Capsules is now Preferred by 14 Blue Cross and Blue Shield (BCBS) Commercial Formularies
Details: Hikma announced the addition of 14 BCBS Plans that have made Mitigare® preferred on their commercial formularies. See the full list of Blue Plans by State and the essential details.
See Details
Effective July 1, 2019
Mitigare® (Colchicine) 0.6 mg Capsules is now Preferred on the South Carolina Medicaid Preferred Drug List (PDL).*
Details: Colcrys® (colchicine, USP) tablets, colchicine tablets and colchicine capsules require prior authorization on South Carolina Medicaid Preferred Drug List (PDL)
Effective May 1, 2019
Generic Colchicine 0.6 mg Capsules are now Preferred on the Louisiana Medicaid Preferred Drug List
Effective April 1, 2019
Mitigare® (Colchicine) 0.6 mg Capsules is Now Preferred on Blue Cross Blue Shield (BCBS) FL, NC and RI Commercial Formularies
Details: Mitigare® is now Preferred on BCBS commercial formularies in Florida, North Carolina and Rhode Island. See the full list of Blue Plans by State and the essential details.
See Details
Effective April 1, 2019
Mitigare® (Colchicine) 0.6 mg Capsules and Generic Colchicine Capsules are now Preferred on the Blue Cross Blue Shield (BCBS) Illinois Community Health Plans*
Details: Colcrys® (colchicine, USP) tablets and colchicine tablets require prior authorization on BCBS Illinois Community Health Plan’s formulary.
Effective Jan 1, 2019
Mitigare® (Colchicine) 0.6 mg Capsules is now Available on Medi-Cal’s Contract Drug List
Colcrys® is a registered trademark of Takeda Pharmaceuticals America, Inc.
